Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Raskin

Showing results (111-120 of 125) with videos related to

Pageof 13
Sort By:
Lancet (London, England)|July 1, 2011
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trialDiane K Wherrett, Brian Bundy, Dorothy J Becker, et al.
Diabetes Care|September 25, 2019
Erratum. Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care 2018;41:1590-1599Erin S LeBlanc, Richard E Pratley, Bess Dawson-Hughes, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
Diabetes Care|June 27, 2018
Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention EffortsErin S LeBlanc, Richard E Pratley, Bess Dawson-Hughes, et al.
Diabetes Care|March 15, 2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled TrialWilliam E Russell, Brian N Bundy, Mark S Anderson, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
Lancet (London, England)|April 9, 2013
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trialsAntoinette Moran, Brian Bundy, Dorothy J Becker, et al.
The New England Journal of Medicine|June 8, 2019
Vitamin D Supplementation and Prevention of Type 2 DiabetesAnastassios G Pittas, Bess Dawson-Hughes, Patricia Sheehan, et al.
Diabetes|January 21, 2026
Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 DiabetesCarla J Greenbaum, S Alice Long, Stephen E Gitelman, et al.
JCI Insight|November 8, 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetesCarla J Greenbaum, Elisavet Serti, Katharina Lambert, et al.
Pageof 13

Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
Lancet (London, England)|July 1, 2011
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trialDiane K Wherrett, Brian Bundy, Dorothy J Becker, et al.
Diabetes Care|September 25, 2019
Erratum. Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care 2018;41:1590-1599Erin S LeBlanc, Richard E Pratley, Bess Dawson-Hughes, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
Diabetes Care|June 27, 2018
Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention EffortsErin S LeBlanc, Richard E Pratley, Bess Dawson-Hughes, et al.
Diabetes Care|March 15, 2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled TrialWilliam E Russell, Brian N Bundy, Mark S Anderson, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
Lancet (London, England)|April 9, 2013
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trialsAntoinette Moran, Brian Bundy, Dorothy J Becker, et al.
The New England Journal of Medicine|June 8, 2019
Vitamin D Supplementation and Prevention of Type 2 DiabetesAnastassios G Pittas, Bess Dawson-Hughes, Patricia Sheehan, et al.
Diabetes|January 21, 2026
Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 DiabetesCarla J Greenbaum, S Alice Long, Stephen E Gitelman, et al.
JCI Insight|November 8, 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetesCarla J Greenbaum, Elisavet Serti, Katharina Lambert, et al.
Pageof 13